C12N 5/0637
Immunosuppressive t lymphocytes
Official title: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
C12N5/0637 (Immunosuppressive t lymphocytes) appears on 354 US grants and 864 published applications in this corpus.
Search patents in C12N- Granted patents
- 354
- Published applications
- 864
- Assignees
- 388
- Inventors
- 1,311
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 0 |
| 2004 | 2 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 0 | 4 |
| 2009 | 0 | 3 |
| 2010 | 1 | 10 |
| 2011 | 0 | 13 |
| 2012 | 0 | 12 |
| 2013 | 3 | 28 |
| 2014 | 7 | 33 |
| 2015 | 7 | 34 |
| 2016 | 15 | 29 |
| 2017 | 20 | 52 |
| 2018 | 26 | 54 |
| 2019 | 21 | 59 |
| 2020 | 31 | 64 |
| 2021 | 33 | 102 |
| 2022 | 26 | 86 |
| 2023 | 38 | 68 |
| 2024 | 53 | 78 |
| 2025 | 42 | 75 |
| 2026 | 27 | 53 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Compositions and methods for hematopoietic stem cell transplants15 Sep 2026US 12,735,678 B2Orca Biosystems, Inc.
- Process for manufacturing of antigen-specific T lymphocytes8 Sep 2026US 12,729,369 B2Gdanski Uniwersytet Medyczny
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Engineered regulatory T cell28 Jul 2026US 12,692,297 B2UCL Business PLC
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Populations of enriched regulatory t cells and methods for producing same1 Oct 2026US 2026/0297523 A1Cellenkos, Inc.
- Compositions, systems and methods for programming immune cell function through targeted gene regulation1 Oct 2026US 2026/0297545 A1Duke University
- Systems and methods for cell culturing24 Sep 2026US 2026/0286267 A1Flaskworks, LLC
- Materials and methods for the manufacture of pluripotent stem cells17 Sep 2026US 2026/0275300 A1Janssen Biotech, Inc.
Most cited
By later US patents
- Method of preparing suppressor T cells with allogeneic mesenchymal stem cells149US 6,281,012 B1Osiris Therapeutics, Inc. · 2001
- Mesenchymal stem cells as immunosuppressants110US 6,797,269 B2Osiris Therapeutics, Inc. · 2004
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016
- Artificial antigen presenting cells and uses therefor105US 7,754,482 B2The Trustees of the University of Pennsylvania · 2010
- Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation95US 6,685,936 B2Osiris Therapeutics, Inc. · 2004